Grimm S - Search Results

1

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.

Dickson R, Boland A, Duarte R, Kotas E, Woolacott N, Hodgson R, Riemsma R, Grimm S, Ramaekers B, Joore M, Büyükkaramikli N, Kaltenthaler E, Stevenson M, Pandor A, Edwards S, Hoyle M, Shepherd J, Armoiry X, Brazzelli M. Dickson R, et al. Among authors: grimm s. Appl Health Econ Health Policy. 2018 Aug;16(4):429-432. doi: 10.1007/s40258-018-0393-7. Appl Health Econ Health Policy. 2018. PMID: 29808296 Free PMC article. No abstract available.

2

Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M, Kaltenthaler E, Ingram JR, Collier F, Ghazavi M. Tappenden P, et al. Among authors: grimm s. Pharmacoeconomics. 2017 Aug;35(8):805-815. doi: 10.1007/s40273-017-0488-2. Pharmacoeconomics. 2017. PMID: 28176188 Free article. Review.

3

Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment.

Lang S, Armstrong N, Deshpande S, Ramaekers B, Grimm S, de Kock S, Kleijnen J, Westwood M. Lang S, et al. Among authors: grimm s. Ann Clin Biochem. 2019 Jan;56(1):72-81. doi: 10.1177/0004563218782722. Epub 2018 Jun 25. Ann Clin Biochem. 2019. PMID: 29848041

4

Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis.

Westwood M, Ramaekers B, Lang S, Grimm S, Deshpande S, de Kock S, Armstrong N, Joore M, Kleijnen J. Westwood M, et al. Among authors: grimm s. Health Technol Assess. 2018 Aug;22(44):1-264. doi: 10.3310/hta22440. Health Technol Assess. 2018. PMID: 30165935 Free PMC article. Review.

5

Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Grimm SE, Armstrong N, Ramaekers BLT, Pouwels X, Lang S, Petersohn S, Riemsma R, Worthy G, Stirk L, Ross J, Kleijnen J, Joore MA. Grimm SE, et al. Pharmacoeconomics. 2019 May;37(5):655-667. doi: 10.1007/s40273-018-0723-5. Pharmacoeconomics. 2019. PMID: 30293207 Review.

6

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Ramaekers BLT, Riemsma R, Grimm S, Fayter D, Deshpande S, Armstrong N, Witlox W, Pouwels X, Duffy S, Worthy G, Kleijnen J, Joore MA. Ramaekers BLT, et al. Among authors: grimm s. Pharmacoeconomics. 2019 Jul;37(7):887-894. doi: 10.1007/s40273-018-0738-y. Pharmacoeconomics. 2019. PMID: 30426463 Free PMC article.

7

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Grimm SE, Fayter D, Ramaekers BLT, Petersohn S, Riemsma R, Armstrong N, Pouwels X, Witlox W, Noake C, Worthy G, Kleijnen J, Joore MA. Grimm SE, et al. Pharmacoeconomics. 2019 Oct;37(10):1195-1207. doi: 10.1007/s40273-019-00792-7. Pharmacoeconomics. 2019. PMID: 30895564 Free PMC article. Review.

8

Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models.

Grimm SE, Pouwels X, Ramaekers BLT, Wijnen B, Knies S, Grutters J, Joore MA. Grimm SE, et al. Pharmacoeconomics. 2020 Feb;38(2):205-216. doi: 10.1007/s40273-019-00855-9. Pharmacoeconomics. 2020. PMID: 31709496 Free PMC article.

9

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Witlox WJA, van Asselt ADI, Wolff R, Armstrong N, Worthy G, Chalker A, Buksnys T, Stirk L, Kleijnen J, Joore MA, Grimm SE. Witlox WJA, et al. Pharmacoeconomics. 2020 Apr;38(4):317-324. doi: 10.1007/s40273-019-00870-w. Pharmacoeconomics. 2020. PMID: 31814080 Free PMC article. Review.

10

Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Wijnen B, Armstrong N, Ramaekers B, Witlox W, Westwood M, Fayter D, Ryder S, Buksnys T, Worthy G, Misso K, Grimm S, Kleijnen J, Joore M. Wijnen B, et al. Among authors: grimm s. Pharmacoeconomics. 2020 Oct;38(10):1043-1053. doi: 10.1007/s40273-020-00932-4. Pharmacoeconomics. 2020. PMID: 32514751 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

653 results

Search Page

Filters